The role of the ubiquitin proteasome system in lymphoma

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 3, 2013, Pages 306-322

  Suh, K Stephen ^a   Tanaka, Takemi ^b   Sarojini, Sreeja ^a   Nightingale, Ginah ^b   Gharbaran, Rajendra ^a   Pecora, Andrew ^a   Goy, Andre ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bortezomib; Carfilzomib; CEP 18770; Clinical trials UPS inhibitors; Lymphoma; Marizomib; Ubiquitin proteasome system

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; IRINOTECAN; MELPHALAN; METHOTREXATE; PALBOCICLIB; PD 022299; PREDNISONE; RAPAMYCIN; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; TOSITUMOMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ANEMIA; ANOREXIA; ANTIGEN PRESENTATION; APOPTOSIS; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOPHAGY; BALANCE IMPAIRMENT; BINDING AFFINITY; BLOOD TOXICITY; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DNA REPAIR; DNA REPLICATION; DRUG RESPONSE; DRUG STRUCTURE; DYSPNEA; EDEMA; ENDOCYTOSIS; FATIGUE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; LYMPHOMA; MAXIMUM TOLERATED DOSE; MENTAL PERFORMANCE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OLIGOMERIZATION; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE;

BORTEZOMIB; CARFILZOMIB; CEP-18770; CLINICAL TRIALS-UPS INHIBITORS; LYMPHOMA; MARIZOMIB; UBIQUITIN PROTEASOME SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LYMPHOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION; UBIQUITIN; UNFOLDED PROTEIN RESPONSE;

EID: 84881668737     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.02.005     Document Type: Review

References (156)

1. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nature Reviews Drug Discovery 2006, 5:596-613.
2. Nandi D., Tahiliani P., Kumar A., Chandu D. The ubiquitin-proteasome system. Journal of Biosciences 2006, 31:137-155.
3. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
4. Ross C.A., Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends in Cell Biology 2004, 14:703-711.
5. Varshavsky A. Regulated protein degradation. Trends in Biochemical Sciences 2005, 30:283-286.
6. Schmidt M., Hanna J., Elsasser S., Finley D. Proteasome-associated proteins: regulation of a proteolytic machine. Biological Chemistry 2005, 386:725-737.
7. Loureiro J., Ploegh H.L. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Advances in Immunology 2006, 92:225-305.
8. Borissenko L., Groll M. Diversity of proteasomal missions: fine tuning of the immune response. Biological Chemistry 2007, 388:947-955.
9. Gao G., Luo H. The ubiquitin-proteasome pathway in viral infections. Canadian Journal of Physiology and Pharmacology 2006, 84:5-14.
10. Shackelford J., Pagano J.S. Targeting of host-cell ubiquitin pathways by viruses. Essays in Biochemistry 2005, 41:139-156.
11. Ambagala A.P., Solheim J.C., Srikumaran S. Viral interference with MHC class I antigen presentation pathway: the battle continues. Veterinary Immunology and Immunopathology 2005, 107:1-15.
12. Watanabe H., Tanaka Y., Shimazu Y., et al. Cell-specific inhibition of paramyxovirus maturation by proteasome inhibitors. Microbiology and Immunology 2005, 49:835-844.
13. Ott D.E., Coren L.V., Sowder R.C., Adams J., Nagashima K., Schubert U. Equine infectious anemia virus and the ubiquitin-proteasome system. Journal of Virology 2002, 76:3038-3044.
14. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chemistry and Biology 2001, 8:739-758.
15. Myung J., Kim K.B., Crews C.M. The ubiquitin-proteasome pathway and proteasome inhibitors. Medicinal Research Reviews 2001, 21:245-273.
16. Yew P.R. Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators. Journal of Cellular Physiology 2001, 187:1-10.
17. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., Nakayama K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. Journal of Biological Chemistry 2001, 276:48937-48943.
18. Tyers M., Jorgensen P. Proteolysis and the cell cycle: with this RING I do thee destroy. Current Opinion in Genetics and Development 2000, 10:54-64.
19. Geisen C., Karsunky H., Yucel R., Moroy T. Loss of p27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis. Oncogene 2003, 22:1724-1729.
20. Martins C.P., Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO Journal 2002, 21:3739-3748.
21. Chiarle R., Budel L.M., Skolnik J., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000, 95:619-626.
22. Seki R., Ohshima K., Nagafuji K., et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. International Journal of Hematology 2010, 91:258-266.
23. Thullberg M., Bartek J., Lukas J. Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle. Oncogene 2000, 19:2870-2876.
24. Helmrich A., Lee S., O'Brien P., et al. Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo. Oncogene 2005, 24:4174-4182.
25. Dunphy C.H. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Archives of Pathology and Laboratory Medicine 2006, 130:483-520.
26. Quintanilla-Martinez L., Kremer M., Keller G., et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. American Journal of Pathology 2001, 159:2095-2105.
27. Sanchez-Beato M., Saez A.I., Navas I.C., et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. American Journal of Pathology 2001, 159:205-213.
28. Visco C., Canal F., Parolini C., et al. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica 2006, 91:687-690.
29. McGarry T.J., Kirschner M.W. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 1998, 93:1043-1053.
30. Obermann E.C., Eward K.L., Dogan A., et al. DNA replication licensing in peripheral B-cell lymphoma. Journal of Pathology 2005, 205:318-328.
31. Pinyol M., Salaverria I., Bea S., et al. Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. International Journal of Cancer 2006, 119:2768-2774.
32. Zhang K.H., Li G.L., Liu Z.Z. Expressions of cell cycle associated factors geminin and cdt1 in patients with acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011, 19:578-581.
33. Bastians H., Topper L.M., Gorbsky G.L., Ruderman J.V. Cell cycle-regulated proteolysis of mitotic target proteins. Molecular Biology of the Cell 1999, 10:3927-3941.
34. Hachem A., Gartenhaus R.B. Oncogenes as molecular targets in lymphoma. Blood 2005, 106:1911-1923.
35. Singer J.D., Gurian-West M., Clurman B., Roberts J.M. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes and Development 1999, 13:2375-2387.
36. Winston J.T., Chu C., Harper J.W. Culprits in the degradation of cyclin E apprehended. Genes and Development 1999, 13:2751-2757.
37. Bai M., Tsanou E., Agnantis N.J., et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas. Histology and Histopathology 2003, 18:449-457.
38. Tzankov A., Gschwendtner A., Augustin F., et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clinical Cancer Research 2006, 12:2125-2132.
39. Marti A., Wirbelauer C., Scheffner M., Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nature Cell Biology 1999, 1:14-19.
40. Molina-Privado I., Rodriguez-Martinez M., Rebollo P., et al. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Research 2009, 69:4052-4058.
41. Rempel R.E., Mori S., Gasparetto M., et al. A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genetics 2009, 5:e1000640.
42. DePamphilis M.L. Review: nuclear structure and DNA replication. Journal of Structural Biology 2000, 129:186-197.
43. Petersen B.O., Wagener C., Marinoni F., et al. Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes and Development 2000, 14:2330-2343.
44. Hoefnagel J.J., Vermeer M.H., Jansen P.M., et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Archives of Dermatology 2005, 141:1139-1145.
45. Xiong X.D., Qiu F.E., Fang J.H., et al. Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. Mutation Research 2009, 662:10-15.
46. Zavitz K.H., Zipursky S.L. Controlling cell proliferation in differentiating tissues: genetic analysis of negative regulators of G1→S-phase progression. Current Opinion in Cell Biology 1997, 9:773-781.
47. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 1999, 13:1501-1512.
48. Bernardi R., Liebermann D.A., Hoffman B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000, 19:2447-2454.
49. Negishi Y., Ui N., Nakajima M., et al. p21Cip-1/SDI-1/WAF-1 gene is involved in chondrogenic differentiation of ATDC5 cells in vitro. Journal of Biological Chemistry 2001, 276:33249-33256.
50. Lavabre-Bertrand T., Henry L., Carillo S., et al. Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 2001, 92:2493-2500.
51. Valbuena J.R., Rassidakis G.Z., Lin P., et al. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Modern Pathology 2005, 18:1343-1349.
52. Shringarpure R., Catley L., Bhole D., et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. British Journal of Haematology 2006, 134:145-156.
53. Robles A.I., Wright M.H., Gandhi B., et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clinical Cancer Research 2006, 12:6547-6556.
54. Valbuena J.R., Gualco G., Espejo-Plascencia I., Medeiros L.J. Classical Hodgkin lymphoma arising in the rectum. Annals of Diagnostic Pathology 2005, 9:38-42.
55. Grimm L.M., Osborne B.A. Apoptosis and the proteasome. Results and Problems in Cell Differentiation 1999, 23:209-228.
56. Naujokat C., Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Laboratory Investigation 2002, 82:965-980.
57. Suzuki Y., Nakabayashi Y., Nakata K., Reed J.C., Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. Journal of Biological Chemistry 2001, 276:27058-27063.
58. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
59. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3850-3855.
60. Degterev A., Boyce M., Yuan J. The channel of death. Journal of Cell Biology 2001, 155:695-698.
61. Degterev A., Lugovskoy A., Cardone M., et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biology 2001, 3:173-182.
62. Tzung S.P., Kim K.M., Basanez G., et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biology 2001, 3:183-191.
63. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 2001, 194:1861-1874.
64. Stoffel A. The NF-kappaB signalling pathway: a therapeutic target in lymphoid malignancies?. Expert Opinion on Therapeutic Targets 2005, 9:1045-1061.
65. Ekiz H.A., Can G., Baran Y. Role of autophagy in the progression and suppression of leukemias. Critical Reviews in Oncology/Hematology 2012, 81:275-285.
66. Amaravadi R.K., Yu D., Lum J.J., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation 2007, 117:326-336.
67. Mihelic R., Kaufman J., Lonial S., Flowers C. Maintenance therapy in lymphoma. Clinical Lymphoma & Myeloma 2007, 7:507-513.
68. Cashen A.F., Bartlett N.L. Therapy of relapsed Hodgkin lymphoma. Blood Reviews 2007, 21:233-243.
69. Fuchs R., Loffler M., Pfreundschuh M., et al. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leukemia and Lymphoma 1994, 14:79-89.
70. Cortelazzo S., Ponzoni M., Ferreri A.J., Dreyling M. Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 2012, 82:78-101.
71. Piccinini M., Tazartes O., Mezzatesta C., et al. Proteasomes are a target of the anti-tumour drug vinblastine. Biochemical Journal 2001, 356:835-841.
72. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
73. Paoluzzi L., O'Connor O.A. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006, 20:13-23.
74. Blade J.S.D., Reece D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology 1998, 102:1115-1123.
75. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology 2005, 23:676-684.
76. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2005, 23:667-675.
77. Chen C.I.K.C., White D., Voralia M., et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007, 25:1570-1575.
78. Maki R.G.K.A., Scheu K., Yamada J., et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103:1431-1438.
79. Davis N.B.T.D., Ansari R.H., Ryan C.W., et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. Journal of Clinical Oncology 2004, 22:115-119.
80. Stevenson J., Nho C.W., Johnson S.W., et al. Effects of Bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a phase II/pharmacodynamic trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, 22:7145.
81. Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113:6069-6076.
82. Kozuch P.S., Rocha-Lima C.M., Dragovich T., et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. Journal of Clinical Oncology 2008, 26:2320-2326.
83. Fowler N., Kahl B.S., Lee P., et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. Journal of Clinical Oncology 2011, 29:3389-3395.
84. Sehn L.H., MacDonald D., Rubin S., et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2011, 29:3396-3401.
85. Williams M.E., Densmore J.J. Biology and therapy of mantle cell lymphoma. Current Opinion in Oncology 2005, 17:425-431.
86. Ludwig H., Hajek R., Tothova E., et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009, 113:3435-3442.
87. Friedberg J.W., Kelly J.L., Neuberg D., et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 2009, 146:282-291.
88. Lamm W., Kaufmann H., Raderer M., et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011, 96:1008-1014.
89. Nabhan C., Villines D., Dalal N., Tolzien K., Kozolff M., Starr A. Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2012, 12:26-31.
90. An J., Sun Y., Fisher M., Rettig M.B. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004, 18:1699-1704.
91. Tobias S.C., Borch R.F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Molecular Pharmaceutics 2004, 1:112-116.
92. Hutter G., Rieken M., Pastore A., et al. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Annals of Hematology 2012, 91:847-856.
93. O'Connor O.A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005, 6:191-199.
94. Goy A.B.S., Kahl B. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology 2005.
95. Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology 2007, 25:4293-4297.
96. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine 2003, 348:2609-2617.
97. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology 2004, 127:165-172.
98. Millenium Pharmaceuticals, Cambridge, MA Product information. Velcade (bortezomib) 2012.
99. Fitzgerald M.F.C., Webb I., Schenkein D., Esseltine D., Weich N. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biology of Blood and Marrow Transplantation 2003, 9:193.
100. Joazeiro C.A., Anderson K.C., Hunter T. Proteasome inhibitor drugs on the rise. Cancer Research 2006, 66:7840-7842.
101. Potts B.C., Albitar M.X., Anderson K.C., et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Current Cancer Drug Targets 2011, 11:254-284.
102. Miller C.P., Ban K., Dujka M.E., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
103. Bichi R., Shinton S.A., Martin E.S., et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:6955-6960.
104. Townsend A., Millward M., Price T., et al. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). Journal of Clinical Oncology 2009, 27:3582.
105. Cusack J.C., Liu R., Xia L., et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clinical Cancer Research 2006, 12:6758-6764.
106. Ruiz S., Krupnik Y., Keating M., Chandra J., Palladino M., McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular Cancer Therapeutics 2006, 5:1836-1843.
107. Slupianek A., Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology 2004, 32:1265-1271.
108. Nencioni A., Wille L., Dal Bello G., et al. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clinical Cancer Research 2005, 11:4259-4265.
109. Jain S., Diefenbach C., Zain J., O'Connor O.A. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evidence 2011, 6:43-57.
110. Dasmahapatra G., Lembersky D., Kramer L., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115:4478-4487.
111. http://clinicaltrials.gov/ct2/show/NCT01276717.
112. Paoluzzi L., Gonen M., Bhagat G., et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008, 112:2906-2916.
113. Kline M.P., Rajkumar S.V., Timm M.M., et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007, 21:1549-1560.
114. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
115. Touzeau C., Dousset C., Bodet L., et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clinical Cancer Research 2011, 17:5973-5981.
116. Rossi M., De Laurenzi V., Munarriz E., et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO Journal 2005, 24:836-848.
117. Heider U., von Metzler I., Kaiser M., et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. European Journal of Haematology 2008, 80:133-142.
118. DuRose J.B., Tam A.B., Niwa M. Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress. Molecular Biology of the Cell 2006, 17:3095-3107.
119. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nature Reviews Drug Discovery 2008, 7:1013-1030.
120. Li X., Zhang K., Li Z. Unfolded protein response in cancer: the physician's perspective. Journal of Hematology & Oncology 2011, 4:8.
121. Ling S.C., Lau E.K., Al-Shabeeb A., et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012, 97:64-72.
122. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
123. Ma Y., Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nature Reviews Cancer 2004, 4:966-977.
124. Roue G., Perez-Galan P., Mozos A., et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011, 117:1270-1279.
125. Bogner C., Ringshausen I., Schneller F., et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. British Journal of Haematology 2003, 122:260-268.
126. Lopes U.G., Erhardt P., Yao R., Cooper G.M. p53-dependent induction of apoptosis by proteasome inhibitors. Journal of Biological Chemistry 1997, 272:12893-12896.
127. de Rozieres S., Maya R., Oren M., Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 2000, 19:1691-1697.
128. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Molecular Carcinogenesis 2006, 45:409-415.
129. MacPherson D., Kim J., Kim T., et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO Journal 2004, 23:3689-3699.
130. Yu D., Carroll M., Thomas-Tikhonenko A. p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood 2007, 109:4936-4943.
131. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
132. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annual Review of Biochemistry 1999, 68:383-424.
133. Cryns V., Yuan J. Proteases to die for. Genes and Development 1998, 12:1551-1570.
134. Porn-Ares M.I., Saido T.C., Andersson T., Ares MP Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells. Biochemical Journal 2003, 374:403-411.
135. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 1999, 5:157-163.
136. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation 2003, 10:66-75.
137. Lenz H.J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treatment Reviews 2003, 29(Suppl 1):41-48.
138. He Q., Huang Y., Sheikh M.S. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004, 23:2554-2558.
139. Zhang H.G., Wang J., Yang X., Hsu H.C., Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004, 23:2009-2015.
140. Ding W.X., Ni H.M., Chen X., Yu J., Zhang L., Yin X.M. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Molecular Cancer Therapeutics 2007, 6:1062-1069.
141. Tang W., Li Y., Yu D., Thomas-Tikhonenko A., Spiegelman V.S., Fuchs S.Y. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Research 2005, 65:1904-1908.
142. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research 2003, 9:1136-1144.
143. Fuchs S.Y., Spiegelman V.S., Kumar K.G. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036.
144. Fuchs S.Y. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biology and Therapy 2002, 1:337-341.
145. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16:1053-1068.
146. Spiegelman V.S., Tang W., Chan A.M., et al. Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. Journal of Biological Chemistry 2002, 277:36624-36630.
147. O'Connor O.A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. Journal of Clinical Oncology 2005, 23:6429-6436.
148. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
149. Lim M.S., Adamson A., Lin Z., et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002, 100:2950-2956.
150. Tsujimoto Y., Gorham J., Cossman J., Jaffe E., Croce C.M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985, 229:1390-1393.
151. Heckman C.A., Mehew J.W., Boxer L.M. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002, 21:3898-3908.
152. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
153. Malaguarnera L., Cristaldi E., Malaguarnera M. The role of immunity in elderly cancer. Critical Reviews in Oncology/Hematology 2010, 74:40-60.
154. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13(18 Pt 1):5291-5294. 10.1158/1078-0432.CCR-07-0871.
155. Furman R.R., Martin P., Ruan J., et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010, 116(23):5432-5439. 10.1002/cncr.25509.
156. Richardson P.G., Hofmeister C., Jakubowiak A., et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). Blood 2009, 114. Abstr 431.